Khaberni - Making the decision to continue or start taking antidepressants during pregnancy is a complex process that requires a delicate balance between the mother's health and potential risks to the fetus.
While many fear the effects of the medications, untreated depression carries significant risks, including poor prenatal healthcare for the mother, premature birth, low birth weight, and increased likelihood of postpartum depression.
According to a recent report from "Mayo Clinic", antidepressants remain a primary treatment option during pregnancy, as the overall risks of birth defects from these medications are very low.
Medical teams usually work to reduce the fetus's exposure to the drug by prescribing a single type of medication at the lowest effective dose possible.
The report emphasizes that the decision to use these medications should be made on a case-by-case basis, weighing the psychological stability against potential side effects.
Medication Options
Mayo Clinic highlights that selective serotonin reuptake inhibitors (SSRIs), such as "Zoloft" and "Lexapro", are generally the first choice. However, some medications like "Paxil" (paroxetine) are usually avoided due to a slight connection to heart defects when taken in the first trimester of pregnancy.
The other options include:
Serotonin and norepinephrine reuptake inhibitors (SNRIs): such as "Effexor", which require careful monitoring of blood pressure.
Bupropion: Not usually a first-line option, but used if other medications fail.
Tricyclic antidepressants: Reserved for cases that have not responded to other types of treatment.
Short-term Risks
Children who were exposed to antidepressants in the third trimester of pregnancy may experience temporary "withdrawal" symptoms after birth, such as tremors or feeding difficulties, which often fade within two weeks.
Mayo Clinic also notes that medication is not the only treatment path; cognitive behavioral therapy (CBT) and regular, safe exercise are effective or complementary alternatives to drug treatment.
